Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response.
Saved in:
| Title: | Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response. |
|---|---|
| Authors: | Zhang L; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany., Wirth M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Patra U; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Stroh J; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany., Isaakidis K; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Rieger L; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany., Kossatz S; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.; Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany., Milanovic M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Zang C; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Demel U; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany., Keiten-Schmitz J; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Wagner K; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Steiger K; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Comparative Experimental Pathology, Institute of Pathology, Technical University of Munich, Munich, Germany., Rad R; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany.; Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technische Universität München, Munich, Germany., Bassermann F; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.; Center for Translational Cancer Research (TranslaTUM), Technische Universität München, Munich, Germany., Müller S; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany., Keller U; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany., Schick M; Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.; Max-Delbrück-Center for Molecular Medicine, Berlin, Germany. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2023 Sep 11; Vol. 15 (9), pp. e16431. Date of Electronic Publication: 2023 Jul 24. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
